Nov 13, 2018
Per Persson comes directly from the role as Chief Commercial Officer of Acarix. Christian Lindholm, who has served as interim CEO since February 2018, resumes his role as Chief Financial Officer. The changes are effective immediately.
“Per has been with the company since July and is already contributing significant leadership to our focused market approach. With a long and successful background in senior positions at global medtech companies, Per adds the competencies we need to take Acarix to the next level, serving patients and healthcare professionals” said Werner Braun, chairman of the board.
Per Persson has more than 25 years of experience from executive sales and marketing positions, such as head of sales at Atos Medical, senior director of marketing at St. Jude Medical and director of the Nordics at Boston Scientific.
“I would also like to thank Christian Lindholm for his dedicated contribution during his tenure as interim CEO, and I am happy that Christian will continue as CFO,” said Werner Braun.
Werner Braun, Chairman of the Board, E-mail: email@example.com, Phone: +49 151 70131343
This information is information that Acarix AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 21:15 CET on 13 November 2018.
Acarix, CADScor®System and cardiac sound measurement
Acarix was established in 2009 and is listed on Nasdaq First North Premier. Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen. Readings are obtained in less than 8 minutes. Safe and suitable for use in both out- and inpatient settings, the CADScor®System thus has the potential to play a major role in patient triage, avoiding the need for many patients to undergo stressful invasive diagnostic procedures.
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, firstname.lastname@example.org) is Certified Advisor of Acarix.